These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 16886901)

  • 1. Process map proposal for the validation of genomic biomarkers.
    Goodsaid F; Frueh F
    Pharmacogenomics; 2006 Jul; 7(5):773-82. PubMed ID: 16886901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated assessment of preclinical data: shifting high attrition rates to earlier phase drug development.
    Korstanje C
    Curr Opin Investig Drugs; 2003 May; 4(5):519-21. PubMed ID: 12833643
    [No Abstract]   [Full Text] [Related]  

  • 3. Provable Data Integrity in the Pharmaceutical Industry Based on Version Control Systems and the Blockchain.
    Steinwandter V; Herwig C
    PDA J Pharm Sci Technol; 2019; 73(4):373-390. PubMed ID: 30770485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of guidance modules by the PDA to extend and/or eliminate periodic validation: a proposal to PDA Scientific Advisory Board.
    Korczynski MS
    PDA J Pharm Sci Technol; 2003; 57(4):245-8. PubMed ID: 14558698
    [No Abstract]   [Full Text] [Related]  

  • 5. Transatlantic regulatory cooperation expanded.
    Hughes B
    Nat Rev Drug Discov; 2007 Aug; 6(8):589-90. PubMed ID: 17821826
    [No Abstract]   [Full Text] [Related]  

  • 6. A prototypical process for creating evidentiary standards for biomarkers and diagnostics.
    Altar CA; Amakye D; Bounos D; Bloom J; Clack G; Dean R; Devanarayan V; Fu D; Furlong S; Hinman L; Girman C; Lathia C; Lesko L; Madani S; Mayne J; Meyer J; Raunig D; Sager P; Williams SA; Wong P; Zerba K
    Clin Pharmacol Ther; 2008 Feb; 83(2):368-71. PubMed ID: 18091762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The application of ICH S6 to the preclinical safety evaluation of plasma derivative therapeutic products.
    Lewis RM; Cavagnaro J
    Biologicals; 2010 Jul; 38(4):494-500. PubMed ID: 20359910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multistep validation process of biomarkers for preclinical drug development.
    Freeman WM; Bixler GV; Brucklacher RM; Lin CM; Patel KM; VanGuilder HD; LaNoue KF; Kimball SR; Barber AJ; Antonetti DA; Gardner TW; Bronson SK
    Pharmacogenomics J; 2010 Oct; 10(5):385-95. PubMed ID: 19997081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving drug manufacturing with process analytical technology.
    Rodrigues LO; Alves TP; Cardoso JP; Menezes JC
    IDrugs; 2006 Jan; 9(1):44-8. PubMed ID: 16374733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA pharmaceutical quality oversight.
    Yu LX; Woodcock J
    Int J Pharm; 2015 Aug; 491(1-2):2-7. PubMed ID: 26027494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemistry, manufacturing, and controls information in NDAs and ANDAs, supplements, annual reports, and other regulatory filings.
    Sheinin E; Williams R
    Pharm Res; 2002 Mar; 19(3):217-26. PubMed ID: 11934225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of documentation requirements for preclinical sections, for marketing submissions in the European Community, Japan and the USA.
    Marr AP; Scales MD
    Adverse Drug React Toxicol Rev; 1993; 12(4):253-62. PubMed ID: 8142578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementing the U.S. FDA guidance on pharmacogenomic data submissions.
    Goodsaid F; Frueh FW
    Environ Mol Mutagen; 2007 Jun; 48(5):354-8. PubMed ID: 17567848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays.
    Viswanathan CT; Bansal S; Booth B; DeStefano AJ; Rose MJ; Sailstad J; Shah VP; Skelly JP; Swann PG; Weiner R
    Pharm Res; 2007 Oct; 24(10):1962-73. PubMed ID: 17458684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarker qualification pilot process at the US Food and Drug Administration.
    Goodsaid F; Frueh F
    AAPS J; 2007 Mar; 9(1):E105-8. PubMed ID: 17408233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International Conference on Harmonisation; Guidance on E16 Biomarkers Related to Drug or Biotechnology Product Development: Context, Structure, and Format of Qualification Submissions; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2011 Aug; 76(155):49773-4. PubMed ID: 21834216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An industry commentary on regulatory issues--microbiology.
    Moldenhauer JE
    PDA J Pharm Sci Technol; 2002; 56(2):60-4. PubMed ID: 11977405
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmaceutical quality assessment.
    Florence AT
    Int J Pharm; 2015 Aug; 491(1-2):1. PubMed ID: 26054801
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA industry relations, a fresh approach.
    Byers TE
    J Parenter Sci Technol; 1983; 37(3):105-6. PubMed ID: 6688270
    [No Abstract]   [Full Text] [Related]  

  • 20. Validation--how much is required?
    Sharp J
    PDA J Pharm Sci Technol; 1995; 49(3):111-8. PubMed ID: 7613988
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.